What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Rob Pieters focuses on Acute lymphocytic leukemia, Immunology, Internal medicine, Leukemia and Cancer research. His Acute lymphocytic leukemia research is multidisciplinary, incorporating elements of Vincristine, Gene expression, Molecular biology and Acute leukemia. He has researched Immunology in several fields, including Chemotherapy and Drug resistance.
Internal medicine connects with themes related to Oncology in his study. His Leukemia study incorporates themes from Gene rearrangement, Chromosomal translocation, Myeloid, Pathology and Myeloid leukemia. His study on Cancer research also encompasses disciplines like
- Mutation and related Mutant and Cell cycle,
- Gene expression profiling which is related to area like Regulation of gene expression and White blood cell.
His most cited work include:
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study (620 citations)
- FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors (541 citations)
- Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment (510 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Immunology, Cancer research, Leukemia and Oncology. His studies in Internal medicine integrate themes in fields like Gastroenterology and Endocrinology. His Immunology study typically links adjacent topics like Drug resistance.
His Leukemia research incorporates elements of Gene expression profiling, Myeloid, Molecular biology, Myeloid leukemia and microRNA. His Oncology research is multidisciplinary, relying on both Cancer, Cohort and Minimal residual disease. His research in Acute lymphocytic leukemia tackles topics such as Vincristine which are related to areas like Daunorubicin.
He most often published in these fields:
- Internal medicine (42.63%)
- Immunology (27.74%)
- Cancer research (24.82%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (42.63%)
- Oncology (18.54%)
- Cancer research (24.82%)
In recent papers he was focusing on the following fields of study:
Rob Pieters mostly deals with Internal medicine, Oncology, Cancer research, Lymphoblastic Leukemia and Immunology. The Oncology study combines topics in areas such as Incidence, Single-nucleotide polymorphism, Survival analysis and Acute lymphocytic leukemia. His biological study spans a wide range of topics, including Haematopoiesis, Protein kinase B, Signal transduction, B cell and Leukemia.
His Leukemia study frequently intersects with other fields, such as Drug resistance. His Lymphoblastic Leukemia research incorporates themes from KMT2A and Pediatrics. His research investigates the connection between Minimal residual disease and topics such as Childhood Acute Lymphoblastic Leukemia that intersect with problems in Pharmacology.
Between 2014 and 2021, his most popular works were:
- Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration (410 citations)
- B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. (97 citations)
- NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. (83 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Rob Pieters spends much of his time researching Internal medicine, Immunology, Cancer research, Leukemia and Hematology. Internal medicine and Oncology are commonly linked in his work. His Oncology research is multidisciplinary, incorporating perspectives in Cancer and White blood cell.
Rob Pieters combines subjects such as Fusion gene, Gene, B cell, Cladribine and Signal transduction with his study of Cancer research. Rob Pieters has included themes like Protein kinase B, Molecular biology, PI3K/AKT/mTOR pathway, PTEN and Drug resistance in his Leukemia study. His research on Hematology also deals with topics like
- Trametinib, Mutant and Pediatrics most often made with reference to Infant Acute Lymphoblastic Leukemia,
- Chemotherapy that intertwine with fields like Treatment outcome and MLL gene rearrangements.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
